The Top 10 Phase III Failures of 2010

By Phase III, researchers are supposed to have a pretty good handle on just how promising an experimental therapy can be. There's proof-of-concept data in the can and some clear indications of just how big a market a new drug can go on to capture.

But even if the odds of success are somewhat better, the risk for losing big is greater as well. A pharma company often steps in to nail down a licensing deal, but late-stage trials typically require large patient populations and consume enormous budgets.

This year's worst Phase III losers are prime examples of just what can go wrong. From Alzheimer's to cancer, investigators are forced time and again to bet on drugs that target mysterious disease triggers.

Late-stage drug development always requires being prepared for the kind of catastrophic failure that can damage big pharma companies and utterly destroy a smaller outfit. Every Phase III trial represents a throw of the dice, here's a look at some of the top programs that rolled snake eyes in 2010.

1. Dimebon
2. Ocrelizumab
3. Taspoglutide
4. Semagacestat
5. ASA404

6. NOV-002
7. Zibotentan
8. Vicriviroc
9. Recentin
10. NV1FGF

Read more on

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.